WO2012121528A3 - Magnetic nanocomposite specific for thyroid cancer and use thereof - Google Patents

Magnetic nanocomposite specific for thyroid cancer and use thereof Download PDF

Info

Publication number
WO2012121528A3
WO2012121528A3 PCT/KR2012/001617 KR2012001617W WO2012121528A3 WO 2012121528 A3 WO2012121528 A3 WO 2012121528A3 KR 2012001617 W KR2012001617 W KR 2012001617W WO 2012121528 A3 WO2012121528 A3 WO 2012121528A3
Authority
WO
WIPO (PCT)
Prior art keywords
thyroid cancer
magnetic nanocomposite
specific
magnetic
nanocomposite
Prior art date
Application number
PCT/KR2012/001617
Other languages
French (fr)
Other versions
WO2012121528A2 (en
Inventor
Jun Ho Choe
Jung Hee Lee
Original Assignee
Samsung Life Public Welfare Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samsung Life Public Welfare Foundation filed Critical Samsung Life Public Welfare Foundation
Publication of WO2012121528A2 publication Critical patent/WO2012121528A2/en
Publication of WO2012121528A3 publication Critical patent/WO2012121528A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1875—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle coated or functionalised with an antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Abstract

The present invention relates to a thyroid cancer-specific magnetic nanocomposite, and more particularly, to a magnetic nanocomposite, in which magnetic nanoparticles are encapsulated in a biocompatible polymer and a thyroid cancer-specific polypeptide is conjugated to the biocompatible polymer, a diagnostic composition for thyroid cancer comprising the magnetic nanocomposite, a therapeutic composition for thyroid cancer comprising the magnetic nanocomposite, a method for providing information for thyroid cancer diagnosis using the magnetic nanocomposite, and a therapeutic method thereof. The magnetic nanocomposite of the present invention is advantageous in that it can be used for diagnosis and treatment of thyroid cancer at the same time.
PCT/KR2012/001617 2011-03-04 2012-03-05 Magnetic nanocomposite specific for thyroid cancer and use thereof WO2012121528A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0019519 2011-03-04
KR20110019519 2011-03-04

Publications (2)

Publication Number Publication Date
WO2012121528A2 WO2012121528A2 (en) 2012-09-13
WO2012121528A3 true WO2012121528A3 (en) 2012-11-01

Family

ID=46798640

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/001617 WO2012121528A2 (en) 2011-03-04 2012-03-05 Magnetic nanocomposite specific for thyroid cancer and use thereof

Country Status (2)

Country Link
KR (1) KR101468769B1 (en)
WO (1) WO2012121528A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103449530A (en) * 2013-09-06 2013-12-18 南京东纳生物科技有限公司 Preparation method of high-performance magnetic manganese zinc ferrite nanostars and nanoclusters
CN103665160B (en) * 2013-12-03 2016-04-13 南昌大学 The method of purifying water soluble nano-sized iron oxide mouse IgG class monoclonal antibody conjugate
WO2015143010A1 (en) * 2014-03-18 2015-09-24 The Trustees Of The University Of Pennsylvania Polyphosphazene delivery system for metal nanocrystals
WO2016015173A1 (en) * 2014-07-29 2016-02-04 北京福纳康生物技术有限公司 Tumor treatment method for blocking tumor vasculature by means of nanomaterial and external radiation source
CN106344115A (en) * 2015-07-17 2017-01-25 成昱 Magnetic knife, and its preparation method and application
AU2016308859A1 (en) * 2015-08-20 2018-02-15 Robert E. Sandstrom Method of attacking target cells
CN105219705B (en) * 2015-09-06 2019-01-04 广州市第一人民医院 Application of the Superparamagnetic Iron Oxide nanoparticle in labeled stem cells
CN105195105A (en) * 2015-09-10 2015-12-30 哈尔滨工业大学宜兴环保研究院 Magnetic nano-adsorbent and preparation method thereof
MX2019005497A (en) * 2016-11-09 2019-11-18 Uti Lp Recombinant pmhc class ii molecules.
US10709792B1 (en) 2018-04-06 2020-07-14 Verily Life Sciences Llc Passivated magnetic nanoparticles for cell targeting and methods of preparation and use
CN109172826A (en) * 2018-10-10 2019-01-11 江苏省肿瘤医院 Targeted nano magnetic grain with heating, chemotherapy and image displaying function and its preparation method and application
CN109091469A (en) * 2018-10-10 2018-12-28 江苏省肿瘤医院 A kind of novel nano drug-loading system preparation method and its application method with heating, chemotherapy and image displaying function
CN109402052B (en) * 2018-10-15 2022-02-22 宁波美晶医疗技术有限公司 Preparation method and application of magnetic nanoparticles for capturing exosomes in blood
CN110922179B (en) * 2019-12-06 2021-01-29 深圳信义磁性材料有限公司 High-permeability low-loss ferrite material and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060163526A1 (en) * 2003-07-10 2006-07-27 Joachim Teller Magnetic nanoparticles having improved magnetic properties
US20060222594A1 (en) * 2005-01-20 2006-10-05 Korea Advanced Institute Of Science And Technology Smart magnetic nanosphere preparation and manufacturing method thereof
US20070112339A9 (en) * 2001-07-25 2007-05-17 Robert Ivkov Magnetic nanoscale particle compositions, and therapeutic methods related thereto
WO2009031859A2 (en) * 2007-09-06 2009-03-12 Anygen Co., Ltd. Multi-functional complex for imaging and drug delivery

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070112339A9 (en) * 2001-07-25 2007-05-17 Robert Ivkov Magnetic nanoscale particle compositions, and therapeutic methods related thereto
US20060163526A1 (en) * 2003-07-10 2006-07-27 Joachim Teller Magnetic nanoparticles having improved magnetic properties
US20060222594A1 (en) * 2005-01-20 2006-10-05 Korea Advanced Institute Of Science And Technology Smart magnetic nanosphere preparation and manufacturing method thereof
WO2009031859A2 (en) * 2007-09-06 2009-03-12 Anygen Co., Ltd. Multi-functional complex for imaging and drug delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L. BARZON ET AL.: "Evaluation of circulating thyroid-specific transcripts as markers of thyroid cancer relapse", INTERNATIONAL JOURNAL OF CANCER, vol. 110, 2004, pages 914 - 920 *

Also Published As

Publication number Publication date
WO2012121528A2 (en) 2012-09-13
KR20120100840A (en) 2012-09-12
KR101468769B1 (en) 2014-12-08

Similar Documents

Publication Publication Date Title
WO2012121528A3 (en) Magnetic nanocomposite specific for thyroid cancer and use thereof
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
HK1178074A1 (en) Compositions and methods for the diagnosis and treatment of tumor
RS20140202A1 (en) Biospecific immunibinders directed against tnf and il-17
MX358321B (en) Anti-ceacam5 antibodies and uses thereof.
EP3046583A4 (en) Virus-like particle conjugates for diagnosis and treatment of tumors
CA2863681A1 (en) Topical use of a skin-commensal prebiotic agent and compositions containing the same
MY188911A (en) Methods of treating bladder cancer
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
MX2013008437A (en) Mri markers, delivery and extraction systems, and methods of manufacture and use thereof.
MX362089B (en) Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof.
MX2015001716A (en) Niclosamide and its derivatives for use in the treatment of solid tumors.
WO2010065329A3 (en) Nanoparticles for cancer treatment
MX357227B (en) Lipid-based nanoparticles.
IL222605A0 (en) Apparatus and kit for encapsulating at least one compound for therapeutic and/or diagnostic use in erythrocytes
WO2012138379A3 (en) Multifunctional chelator-free radioactive nanoparticles for imaging and therapy
IL240560A0 (en) Compositions and methods for the diagnosis and treatment of tumor
HK1201045A1 (en) Compositions and methods for the diagnosis and treatment of tumor
EP2548888A4 (en) Periodontal-disease-specific peptide, and treatment and diagnosis of periodontal disease using same
WO2010086838A3 (en) Non-ad5 adenoviral vectors and methods and uses related thereto
WO2012018866A3 (en) Methods and compositions for the diagnosis and treatment of breast cancer
WO2011107866A3 (en) Silyl-derivatives of polysaccharides
ZA201209452B (en) Gold complexes for use in the treatment of cancer
WO2011085134A3 (en) Methods and compositions for the diagnosis, prognosis and treatment of cancer
IN2012DE00138A (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12754524

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12754524

Country of ref document: EP

Kind code of ref document: A2